Cargando…
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827924/ https://www.ncbi.nlm.nih.gov/pubmed/33430081 http://dx.doi.org/10.3390/ph14010044 |
_version_ | 1783640885563490304 |
---|---|
author | Rao, Praveen P. N. Pham, Amy Trinh Shakeri, Arash El Shatshat, Amna Zhao, Yusheng Karuturi, Rahul C. Hefny, Ahmed A. |
author_facet | Rao, Praveen P. N. Pham, Amy Trinh Shakeri, Arash El Shatshat, Amna Zhao, Yusheng Karuturi, Rahul C. Hefny, Ahmed A. |
author_sort | Rao, Praveen P. N. |
collection | PubMed |
description | The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as superior patient compliance for oral therapies, reduced manufacturing costs and ease of large scale distribution due to better stability and storage profiles. Discovering new drugs for SARS-CoV-2 infections is a time consuming and expensive proposition. In this regard, drug repurposing is an appealing approach which can provide rapid access to therapeutics with proven record of safety and efficacy. We investigated the drug repurposing potential of a library of dipeptidyl peptidase 4 (DPP4) inhibitors which are currently marketed for type-2 diabetes as treatment option for SARS-CoV-2 infections. These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M(pro) viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M(pro) and MERS-CoV CL(pro) suggesting their potential to be repurposed as broad-spectrum antiviral agents. |
format | Online Article Text |
id | pubmed-7827924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78279242021-01-25 Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection Rao, Praveen P. N. Pham, Amy Trinh Shakeri, Arash El Shatshat, Amna Zhao, Yusheng Karuturi, Rahul C. Hefny, Ahmed A. Pharmaceuticals (Basel) Article The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as superior patient compliance for oral therapies, reduced manufacturing costs and ease of large scale distribution due to better stability and storage profiles. Discovering new drugs for SARS-CoV-2 infections is a time consuming and expensive proposition. In this regard, drug repurposing is an appealing approach which can provide rapid access to therapeutics with proven record of safety and efficacy. We investigated the drug repurposing potential of a library of dipeptidyl peptidase 4 (DPP4) inhibitors which are currently marketed for type-2 diabetes as treatment option for SARS-CoV-2 infections. These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 M(pro) viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV M(pro) and MERS-CoV CL(pro) suggesting their potential to be repurposed as broad-spectrum antiviral agents. MDPI 2021-01-08 /pmc/articles/PMC7827924/ /pubmed/33430081 http://dx.doi.org/10.3390/ph14010044 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rao, Praveen P. N. Pham, Amy Trinh Shakeri, Arash El Shatshat, Amna Zhao, Yusheng Karuturi, Rahul C. Hefny, Ahmed A. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title_full | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title_fullStr | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title_full_unstemmed | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title_short | Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection |
title_sort | drug repurposing: dipeptidyl peptidase iv (dpp4) inhibitors as potential agents to treat sars-cov-2 (2019-ncov) infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827924/ https://www.ncbi.nlm.nih.gov/pubmed/33430081 http://dx.doi.org/10.3390/ph14010044 |
work_keys_str_mv | AT raopraveenpn drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT phamamytrinh drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT shakeriarash drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT elshatshatamna drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT zhaoyusheng drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT karuturirahulc drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection AT hefnyahmeda drugrepurposingdipeptidylpeptidaseivdpp4inhibitorsaspotentialagentstotreatsarscov22019ncovinfection |